State of Wisconsin Investment Board bought a new position in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 26,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $478,000. State of Wisconsin Investment Board owned approximately 0.07% of AMAG Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Sei Investments Co. increased its position in shares of AMAG Pharmaceuticals by 0.7% in the first quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock worth $188,000 after acquiring an additional 54 shares in the last quarter. Louisiana State Employees Retirement System boosted its holdings in shares of AMAG Pharmaceuticals by 1.4% during the first quarter. Louisiana State Employees Retirement System now owns 14,000 shares of the specialty pharmaceutical company’s stock worth $316,000 after purchasing an additional 200 shares during the period. Arizona State Retirement System boosted its holdings in shares of AMAG Pharmaceuticals by 1.7% during the first quarter. Arizona State Retirement System now owns 17,900 shares of the specialty pharmaceutical company’s stock worth $404,000 after purchasing an additional 300 shares during the period. Municipal Employees Retirement System of Michigan boosted its holdings in shares of AMAG Pharmaceuticals by 6.6% during the second quarter. Municipal Employees Retirement System of Michigan now owns 8,280 shares of the specialty pharmaceutical company’s stock worth $152,000 after purchasing an additional 510 shares during the period. Finally, Mason Street Advisors LLC boosted its holdings in shares of AMAG Pharmaceuticals by 7.4% during the first quarter. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock worth $181,000 after purchasing an additional 554 shares during the period.

COPYRIGHT VIOLATION WARNING: “State of Wisconsin Investment Board Takes Position in AMAG Pharmaceuticals, Inc. (AMAG)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.dailypolitical.com/2017/09/13/state-of-wisconsin-investment-board-takes-position-in-amag-pharmaceuticals-inc-amag.html.

Several analysts recently commented on the stock. ValuEngine upgraded shares of AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, July 25th. Citigroup Inc. decreased their price target on shares of AMAG Pharmaceuticals to $24.00 and set a “hold” rating for the company in a report on Friday, July 7th. Zacks Investment Research cut shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 26th. Barclays PLC restated an “equal weight” rating and set a $20.00 price target (down from $25.00) on shares of AMAG Pharmaceuticals in a report on Thursday, June 1st. Finally, Deutsche Bank AG set a $24.00 price target on shares of AMAG Pharmaceuticals and gave the stock a “hold” rating in a report on Friday, July 7th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $27.92.

Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) opened at 20.30 on Wednesday. The firm’s market capitalization is $716.35 million. AMAG Pharmaceuticals, Inc. has a 1-year low of $16.00 and a 1-year high of $36.83. The firm has a 50-day moving average of $18.15 and a 200-day moving average of $19.94.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.18. The company had revenue of $158.39 million during the quarter, compared to analysts’ expectations of $158.83 million. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The business’s quarterly revenue was up 24.3% on a year-over-year basis. During the same period last year, the business earned $1.45 EPS. On average, equities research analysts anticipate that AMAG Pharmaceuticals, Inc. will post ($1.38) EPS for the current fiscal year.

In other news, SVP Julie Krop sold 4,938 shares of the firm’s stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $20.00, for a total transaction of $98,760.00. Following the completion of the transaction, the senior vice president now directly owns 28,336 shares of the company’s stock, valued at approximately $566,720. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 3.80% of the stock is owned by company insiders.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.